Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Conditions
Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease · Advanced Gastrointestinal Stromal Tumor · HIF-2α Mutated Cancers
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California, United States
Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois, United States
Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville, Illinois, United States
University of Iowa ( Site 0104), Iowa City, Iowa, United States
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore, Maryland, United States
National Institutes of Health ( Site 0125), Bethesda, Maryland, United States
Massachusetts General Hospital ( Site 0111), Boston, Massachusetts, United States
University of Michigan ( Site 0126), Ann Arbor, Michigan, United States
Washington University-Internal Medicine/Oncology ( Site 0124), St Louis, Missouri, United States
Icahn School of Medicine at Mount Sinai ( Site 0123), New York, New York, United States
Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127), Philadelphia, Pennsylvania, United States
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
Vanderbilt University Medical Center ( Site 0107), Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center ( Site 0112), Houston, Texas, United States
Prince of Wales Hospital-Medical Oncology ( Site 1601), Randwick, New South Wales, Australia
The Royal Melbourne Hospital ( Site 1602), Parkville, Victoria, Australia
Arthur J.E. Child Comprehensive Cancer Centre ( Site 0203), Calgary, Alberta, Canada
Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, Canada
FALP ( Site 2200), Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 2203), Santiago, Region M. de Santiago, Chile
Peking University First Hospital-Urology ( Site 1900), Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center ( Site 1905), Guangzhou, Guangdong, China
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1904), Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University ( Site 1906), Chengdu, Sichuan, China
Rigshospitalet ( Site 0304), Copenhagen, Capital Region, Denmark
Rigshospitalet-Department of Endocrinology ( Site 0303), Copenhagen, Capital Region, Denmark
Odense Universitetshospital ( Site 0302), Odense, Region Syddanmark, Denmark
CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402), Strasbourg, Alsace, France
Hôpital Edouard Herriot-oncologie ( Site 0405), Lyon, Auvergne-Rhône-Alpes, France
Institut Paoli-Calmettes-Oncology ( Site 0406), Marseille, Bouches-du-Rhone, France
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0407), Le Kremlin-Bicêtre, Paris, France
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0404), Paris, France
Gustave Roussy ( Site 0403), Villejuif, Île-de-France Region, France
Universitaetsklinikum Freiburg ( Site 0504), Freiburg im Breisgau, Baden-Wurttemberg, Germany
Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Department of Internal Medicine IV, Division ( Site 0501), München, Bavaria, Germany
Comprehensive Cancer Center Mainfranken-Div. of Endocrinology and Diabetes ( Site 0500), Würzburg, Bavaria, Germany
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 0505), Düsseldorf, North Rhine-Westphalia, Germany
Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism ( Site 0503), Berlin, Germany
Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály ( Site 0600), Budapest, Hungary
Sheba Medical Center-Institute of Endocrinology, Diabetes and Metabolism ( Site 1400), Ramat Gan, Israel
Sourasky Medical Center ( Site 1401), Tel Aviv, Israel
University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704), Naples, Campania, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-S.C. Oncologia Medica 2- Sarcomi ( Site 0709), Milan, Lombardy, Italy
Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 0706), Siena, Tuscany, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0708), Bologna, Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0701), Brescia, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 0705), Milan, Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroe ( Site 0700), Milan, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 0703), Verona, Italy
Hokkaido University Hospital ( Site 1800), Sapporo, Hokkaido, Japan
Yokohama City University Hospital ( Site 1804), Yokohama, Kanagawa, Japan
Kochi Medical School Hospital ( Site 1807), Nankoku, Kochi, Japan
National Cancer Center Hospital ( Site 1802), Chuo-ku, Tokyo, Japan
Kyoto University Hospital ( Site 1806), Kyoto, Japan
Tokyo Women's Medical University Adachi Medical Center ( Site 1803), Tokyo, Japan
Universitair Medisch Centrum Utrecht ( Site 1530), Utrecht, Netherlands
Oslo Universitetssykehus Radiumhospitalet ( Site 2400), Oslo, Norway
START Lisbon - Hospital de Santa Maria ( Site 2601), Lisbon, Lisbon District, Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2600), Porto, Portugal
GBUZ Republican Clinical Oncological Dispensary ( Site 0804), Ufa, Baskortostan, Respublika, Russia
Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov ( Site 0805), Saint Petersburg, Leningradskaya Oblast', Russia
Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 0803), Saint Petersburg, Leningradskaya Oblast', Russia
Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 0801), Moscow, Moscow, Russia
Endocrinology Research Center of Rosmedtechnologies-Surgery ( Site 0809), Moscow, Moscow, Russia
National Cancer Centre Singapore ( Site 1700), Singapore, Central Singapore, Singapore
Seoul National University Hospital ( Site 2001), Jongno-gu, Seoul, South Korea
Asan Medical Center ( Site 2000), Songpa-gu, Seoul, South Korea
MD Anderson Cancer Center-Oncology ( Site 1102), Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1103), Madrid, Madrid, Comunidad de, Spain
Hospital Universitario Central de Asturias-Medical Oncology ( Site 1101), Oviedo, Principality of Asturias, Spain
Hospital Universitari Vall d'Hebron ( Site 1100), Barcelona, Spain
Skanes University Hospital Lund ( Site 1200), Lund, Skåne County, Sweden
Karolinska Universitetssjukhuset Solna ( Site 1202), Stockholm, Stockholm County, Sweden
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1201), Uppsala, Uppsala County, Sweden
Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 1204), Gothenburg, Västra Götaland County, Sweden
Baskent University Adana Training Hospital ( Site 0906), Yüreğir, Adana, Turkey (Türkiye)
Ege University Medicine of Faculty ( Site 0900), Bornova, İzmir, Turkey (Türkiye)
Hacettepe Universitesi-oncology hospital ( Site 0901), Ankara, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi. ( Site 0904), Ankara, Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 0902), Istanbul, Turkey (Türkiye)
Addenbrooke's Hospital ( Site 1309), Cambridge, Cambridgeshire, United Kingdom
Royal Free Hospital ( Site 1302), London, England, United Kingdom
The Beatson West of Scotland Cancer Centre ( Site 1308), Glasgow, Glasgow City, United Kingdom
Hammersmith Hospital-Medical Oncology ( Site 1304), London, London, City of, United Kingdom
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC